FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293582013> ?p ?o ?g. }

• W4293582013 abstract "Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant protein of the anti-vascular endothelial growth factor (VEGF) family, has been approved in clinical application among mCRC patients since 2012. A comprehensive analysis of the efficacy, safety, and cost-effectiveness of aflibercept in mCRC treatment is necessary. Objective: To evaluate the efficacy, safety, and cost-effectiveness of aflibercept for the treatment of mCRC in order to provide a decision-making reference for the selection of targeted drugs for second-line treatment of mCRC in Hong Kong, Macao, and Taiwan regions of China and the selection of new drugs for medical institutions in these regions. Methods: A systematic retrieve on databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, and Weipu, as well as relevant websites and databases of health technology assessment including the National Institute of Health and Clinical Optimization, Centre for Evaluation and Communication at the University of York, and the Canadian Agency for Medicines and Health Technology, was conducted. The literature was screened according to the inclusion and exclusion criteria, and data were extracted and analyzed by two authors, while the quality of the literature was assessed. Results: Finally, we included two HTA reports, 11 systematic reviews/meta-analyses, and two cost-effectiveness studies in the rapid health technology assessment. For mCRC patients receiving second-line treatment, aflibercept combined with FOLFIRI significantly increased progression-free survival (PFS) and overall survival (OS) and the objective response rate (ORR) also improved, compared with folinic acid + fluorouracil + irinotecan (FOLFIRI). In terms of safety, mCRC patients who received aflibercept combined with FOLFIRI therapy had a higher incidence of grade 3-4 adverse events than those who received FOLFIRI alone, including anti-VEGF-related adverse events (hypertension, hemorrhagic events, and proteinuria) and chemotherapy-related adverse events (diarrhea, weakness, stomatitis, hand-foot syndrome, neutropenia, and thrombocytopenia). In terms of cost-effectiveness, two economic studies conducted in the United Kingdom and Japan, respectively, found that compared with FOLFIRI, aflibercept combined with FOLFIRI had no cost-effectiveness advantage in mCRC patients receiving second-line treatment. Conclusion: Compared with FOLFIRI treatment, aflibercept combined with FOLFIRI for the second-line treatment of mCRC patients has better efficacy, worse safety, and is not cost-effective. More high-quality clinical studies are required for further exploration of aflibercept's clinical value. Medical institutions in Hong Kong, Macao, and Taiwan regions of China should be cautious when using or introducing aflibercept plus FOLFIRI as a mCRC treatment." @default.
• W4293582013 created "2022-08-30" @default.
• W4293582013 creator A5002553102 @default.
• W4293582013 creator A5017122175 @default.
• W4293582013 creator A5049270514 @default.
• W4293582013 creator A5055401170 @default.
• W4293582013 creator A5057674674 @default.
• W4293582013 creator A5081313743 @default.
• W4293582013 creator A5086484316 @default.
• W4293582013 creator A5087207493 @default.
• W4293582013 date "2022-08-30" @default.
• W4293582013 modified "2023-09-29" @default.
• W4293582013 title "Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment" @default.
• W4293582013 cites W1492286179 @default.
• W4293582013 cites W1618389625 @default.
• W4293582013 cites W1940111737 @default.
• W4293582013 cites W1970671696 @default.
• W4293582013 cites W1977675372 @default.
• W4293582013 cites W1978432535 @default.
• W4293582013 cites W1980725734 @default.
• W4293582013 cites W1990423062 @default.
• W4293582013 cites W2021606401 @default.
• W4293582013 cites W2047963211 @default.
• W4293582013 cites W2060587247 @default.
• W4293582013 cites W2115735904 @default.
• W4293582013 cites W2120291439 @default.
• W4293582013 cites W2131794175 @default.
• W4293582013 cites W2140583113 @default.
• W4293582013 cites W2143025931 @default.
• W4293582013 cites W2155492044 @default.
• W4293582013 cites W2163515835 @default.
• W4293582013 cites W2756578555 @default.
• W4293582013 cites W2800080844 @default.
• W4293582013 cites W2810482352 @default.
• W4293582013 cites W2885744892 @default.
• W4293582013 cites W2913797367 @default.
• W4293582013 cites W2925884937 @default.
• W4293582013 cites W2933970205 @default.
• W4293582013 cites W3005232660 @default.
• W4293582013 cites W3039434812 @default.
• W4293582013 cites W3041082129 @default.
• W4293582013 cites W3048100495 @default.
• W4293582013 cites W3049608122 @default.
• W4293582013 cites W3128646645 @default.
• W4293582013 cites W3134887329 @default.
• W4293582013 cites W3199488557 @default.
• W4293582013 cites W4211133582 @default.
• W4293582013 cites W4244315786 @default.
• W4293582013 doi "https://doi.org/10.3389/fphar.2022.914683" @default.
• W4293582013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36110513" @default.
• W4293582013 hasPublicationYear "2022" @default.
• W4293582013 type Work @default.
• W4293582013 citedByCount "0" @default.
• W4293582013 crossrefType "journal-article" @default.
• W4293582013 hasAuthorship W4293582013A5002553102 @default.
• W4293582013 hasAuthorship W4293582013A5017122175 @default.
• W4293582013 hasAuthorship W4293582013A5049270514 @default.
• W4293582013 hasAuthorship W4293582013A5055401170 @default.
• W4293582013 hasAuthorship W4293582013A5057674674 @default.
• W4293582013 hasAuthorship W4293582013A5081313743 @default.
• W4293582013 hasAuthorship W4293582013A5086484316 @default.
• W4293582013 hasAuthorship W4293582013A5087207493 @default.
• W4293582013 hasBestOaLocation W42935820131 @default.
• W4293582013 hasConcept C121608353 @default.
• W4293582013 hasConcept C126322002 @default.
• W4293582013 hasConcept C143998085 @default.
• W4293582013 hasConcept C177713679 @default.
• W4293582013 hasConcept C2776478404 @default.
• W4293582013 hasConcept C2776694085 @default.
• W4293582013 hasConcept C2776705615 @default.
• W4293582013 hasConcept C2776738588 @default.
• W4293582013 hasConcept C2777802072 @default.
• W4293582013 hasConcept C2778749236 @default.
• W4293582013 hasConcept C2780259306 @default.
• W4293582013 hasConcept C526805850 @default.
• W4293582013 hasConcept C71924100 @default.
• W4293582013 hasConcept C95190672 @default.
• W4293582013 hasConceptScore W4293582013C121608353 @default.
• W4293582013 hasConceptScore W4293582013C126322002 @default.
• W4293582013 hasConceptScore W4293582013C143998085 @default.
• W4293582013 hasConceptScore W4293582013C177713679 @default.
• W4293582013 hasConceptScore W4293582013C2776478404 @default.
• W4293582013 hasConceptScore W4293582013C2776694085 @default.
• W4293582013 hasConceptScore W4293582013C2776705615 @default.
• W4293582013 hasConceptScore W4293582013C2776738588 @default.
• W4293582013 hasConceptScore W4293582013C2777802072 @default.
• W4293582013 hasConceptScore W4293582013C2778749236 @default.
• W4293582013 hasConceptScore W4293582013C2780259306 @default.
• W4293582013 hasConceptScore W4293582013C526805850 @default.
• W4293582013 hasConceptScore W4293582013C71924100 @default.
• W4293582013 hasConceptScore W4293582013C95190672 @default.
• W4293582013 hasLocation W42935820131 @default.
• W4293582013 hasLocation W42935820132 @default.
• W4293582013 hasLocation W42935820133 @default.
• W4293582013 hasOpenAccess W4293582013 @default.
• W4293582013 hasPrimaryLocation W42935820131 @default.
• W4293582013 hasRelatedWork W1792988773 @default.
• W4293582013 hasRelatedWork W2014795358 @default.
• W4293582013 hasRelatedWork W2029464197 @default.
• W4293582013 hasRelatedWork W2101986864 @default.

• next